Provided by Tiger Trade Technology Pte. Ltd.

Relmada Therapeutics, Inc.

4.58
-0.0500-1.08%
Post-market: 4.580.00000.00%19:30 EDT
Volume:935.75K
Turnover:4.24M
Market Cap:490.06M
PE:-4.92
High:4.64
Open:4.64
Low:4.38
Close:4.63
52wk High:8.00
52wk Low:0.5950
Shares:107.00M
Float Shares:78.16M
Volume Ratio:1.08
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9300
EPS(LYR):-1.4535
ROE:-55.66%
ROA:-32.39%
PB:2.37
PE(LYR):-3.15

Loading ...

BRIEF-Relmada Therapeutics Q4 EPS USD -0.27

Reuters
·
Mar 20

Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Dow Jones
·
Mar 20

Relmada Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Mar 18

Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors

TIPRANKS
·
Mar 18

Relmada’s Withdrawn BOOST Trial Resets Expectations for NDV-01 and RLMD

TIPRANKS
·
Mar 18

Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD)

TIPRANKS
·
Mar 14

Relmada Therapeutics to Host Fourth-Quarter 2025 Financial Results Call and Webcast

Reuters
·
Mar 12

A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer Data

Simply Wall St.
·
Mar 10

Top Midday Gainers

MT Newswires Live
·
Mar 10

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Reuters
·
Mar 09

Relmada Therapeutics Shares up 41% After Co's Bladder Cancer Drug Shows Promising Mid‑Stage Data

THOMSON REUTERS
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

Reuters
·
Mar 09

Why Is Relmada Therapeutics Stock Soaring Monday?

Benzinga_recent_news
·
Mar 09

Relmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement

Dow Jones
·
Mar 09

Why Is Relmada Therapeutics Stock (RLMD) Up Today?

TIPRANKS
·
Mar 09

Relmada Therapeutics Launches PIPE Financing to Raise $160 Million

MT Newswires Live
·
Mar 09

Relmada Therapeutics Shares up 27% to $5.66 Premarket After Bladder Cancer Drug Shows Promising Mid‑Stage Data

THOMSON REUTERS
·
Mar 09

BUZZ-Relmada Therapeutics surges premarket as bladder cancer drug shows promising mid‑stage data

Reuters
·
Mar 09

Press Release: Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Dow Jones
·
Mar 09

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for Ndv-01 in Non-Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Mar 09